key: cord-0978334-gw2y3mwx
authors: Ilonzo, Nicole; Rao, Ajit; Safir, Scott; Vouyouka, Ageliki; Phair, John; Baldwin, Melissa; Ting, Windsor; Soundararajan, Krishna; Han, Daniel; Tadros, Rami; Marin, Michael; Faries, Peter
title: Acute Thrombotic Manifestations of COVID-19 Infection: Experience at a Large New York City Health System
date: 2020-09-01
journal: J Vasc Surg
DOI: 10.1016/j.jvs.2020.08.038
sha: db853094ce1dcd778279ed374243471cdfe3fedd
doc_id: 978334
cord_uid: gw2y3mwx

INTRODUCTION: COVID-19 is a novel coronavirus which typically results in upper respiratory symptoms. However, we describe the acute arterial and venous thrombotic events following COVID-19 infection. Managing acute thrombotic events from the novel virus presents unprecedented challenges during the COVID-19 pandemic. Our study highlights the unique management of these patients and discusses the role of anticoagulation in patients diagnosed with COVID-19. METHODS: Data for 21 patients with laboratory confirmed COVID-19 disease and acute venous or arterial thrombosis were collected. Patients were analyzed on the basis of demographics, comorbidities, home medications, laboratory markers, and outcomes. The primary postoperative outcome of interest was mortality and secondary outcomes were primary patency and morbidity. To assess for significance, univariate analysis was performed using Pearson χ2 and Fisher exact tests for categorical variables and Student t-test for continuous variables. RESULTS: 21 patients with acute thrombotic events met our inclusion and exclusion criteria. The majority of cases were acute arterial events (76.2%) while the remainder were venous cases (23.8%). The average age of all patients was 64.6 years-old and 52.4% were male. The most prevalent comorbidity in the group was hypertension (81.0%). Several markers were markedly abnormal in both arterial and venous cases, including an elevated neutrophil: lymphocyte ratio (8.8) and d-dimer (4.9 mcg/mL). Operative intervention included percutaneous angiogram in 25.00% of patients and open surgical embolectomy in 23.8%. The majority of arterial interventions had a postoperative complication (53.9%) versus a 0% complication in the venous interventions. AKI on admission was a factor in 75.0% of mortalities versus 18.2% in survivors (p=0.04). CONCLUSION: We describe our experience in the epicenter of the pandemic of 21 patients who experienced major thrombotic events from COVID-19. Our cohort highlights the need for increased awareness of vascular manifestations of COVID-19 and the important role of anticoagulation in these patients. More data is urgently needed to optimize treatments and prevent further vascular complications of COVID-19 infections.

The 2019 novel corona virus has resulted in a pandemic that has 2 overwhelmed many health systems across the world. 1 As of June 21 st , 2020, there have been over 3 two million cases in the United States with over 200,000 cases in New York City (NYC) alone 2.

NYC was the epicenter of the pandemic and had more COVID-19 cases than many other 5 countries in the world. 3 Mount Sinai Health System is in the heart of NYC and as a result has 6 experienced a high volume of COVID-19 patients. 7 COVID-19 has a wide range of recognized presentations from asymptomatic carriers to 8 upper respiratory symptoms. In severe cases, the virus can result in Acute Respiratory Distress 9 Syndrome (ARDS), sepsis, and death 4 . There is also increasing evidence that patients with 10 COVID-19 infection appear to have a virus-induced hypercoagulability which results in 11 significant thrombotic events 5. Initial reports showed that anticoagulation may result in decreased 12 mortality in patients with COVID-19 6 presumably by reducing pulmonary embolism and 13 thrombotic complications. 7 The mechanism of thrombosis is still incompletely elucidated but is 14 thought to involve dysregulation of the clotting cascade as well as endothelial dysfunction 8 and 15 endotheliitis. 9 

At the start of the pandemic, there was a noticeable increase in the number of vascular 17 surgery consultations at our institution for acute large vessel thrombosis in both the arterial and 18 venous circulation. We describe our experiences with laboratory confirmed COVID-19 patients 19 who experienced an acute vascular event. Managing acute thrombotic events from the novel 20 virus presents unprecedented challenges during the COVID-19 pandemic. Our study highlights 21 the thrombotic complications of COVID-19, unique management of these patients, and discusses Patients with laboratory-confirmed COVID-19 infections using Polymerase Chain Reaction 6 (PCR) testing were selected. Patients who tested negative for COVID-19 despite respiratory 7 symptoms were excluded. Any patient with chronic respiratory symptoms without an acute 8 component occurring within two weeks were excluded. Mild COVID-19 infection was defined 9 as a hospitalized patient with SpO 2 greater than 94% and no radiographic evidence of 10 pneumonia. Moderate COVID-19 infection was defined as hospitalized patients with hypoxia 11 (SpO 2 less than or equal to 94%) or radiographic evidence of pneumonia. Severe COVID-19 12 infection was defined as patient requiring more than nasal cannula to maintain oxygen saturation 13 or mechanical ventilation. These definitions are modified from established 14 classifications. 10, 11 Thrombotic events were subdivided into arterial and venous classifications. 15 Statistical Analysis 16 Patients were analyzed on the basis of demographics, comorbidities, home medications, 17 laboratory markers, and outcomes. The primary postoperative outcome of interest was mortality. 18 The secondary postoperative outcomes of interest were primary patency and morbidity. To 19 assess for significance in patient demographics, comorbidities, home medications, laboratory 20 markers, and outcomes, univariate analysis was performed using Pearson χ2 and Fisher exact 21 tests for categorical variables and Student t-test for continuous variables. P value of < .05 was 22 J o u r n a l P r e -p r o o f 8 considered to be statistically significant. All analyses were performed with SAS 9.4 (Cary, NC). 1 IRB approval was obtained for this study. 

The daily number of hospitalized patients with COVID-19 in the health system during 5 this study period ranged between 900 to 2000 patients. From these hospitalized patients, there 6 were over 30 vascular consultations in COVID-19 positive of which 21 patients with acute 7 thrombotic events met our inclusion and exclusion criteria (Table 1 ). 14 patients (66.7%) were 8 admitted for a thrombotic event and found to have COVID-19. The remaining 7 patients were 9 admitted initially for COVID-19 and subsequently developed a thrombotic event. The majority 10 of cases were acute arterial events (76.2%) while the remainder were venous cases (23.8%). The 11 average age of all patients was 64.6 years-old and 52.4% were male. The majority of patients 12 were either Caucasian (28.6%), African-American (28.6%), or Hispanic (28.6%). No Asian 13 patients presented with arterial events (0% vs. 60%, p=.008). There was a trend toward more 14 venous events in women (60% vs. 40%, p=0.70). The majority of patients were on an antiplatelet 15 (76.2%) or anticoagulant (19.1%) agent prior to admission. 23.8% of patients were on 16 clopidogrel prior to admission and 52.4% were on aspirin. 19.1% were on anticoagulation prior 17 to admission. The indications for preoperative anticoagulation include atrial fibrillation and 18 history of deep vein thrombosis. All patients who underwent revascularization were started on 19 anticoagulation preoperatively. Of the four mortalities, two of these patients were on 20 subcutaneous heparin at 5000U q12 hours after surgery. One was on enoxaparin 40 mg daily for 21 3 days. The final patient was on apixaban at home. 22 J o u r n a l P r e -p r o o f 9 As seen in Table 2 , the most prevalent comorbidity in the group was hypertension (81.0 1 %). Other common presenting medical problems included hyperlipidemia (66.7%), diabetes 2 mellitus (47.5%), acute renal failure (47.6%), and current or former smokers (81.0%). There 3 were no significant differences in comorbidities between arterial and venous cases. Average Several laboratory values were markedly abnormal in both arterial and venous cases, 7 including an elevated neutrophil: lymphocyte ratio (8.8), d-dimer (4.9 mcg/mL), fibrinogen 8 (634.1 mg/dL), ferritin (929.1 ng/mL), and lactate dehydrogenase (516.6 U/L) ( Table 3) . 9 Procalcitonin levels differed significantly between the arterial and venous group (19.34 ng/ml vs. 10 0.08 ng/mL, p<.01). Of note, 85.7% of patients presented with lymphopenia on admission. 11 The most frequently involved arterial segment was the femoropopliteal region (38.1%) 12 ( Table 4 ). Two patients underwent thrombolysis (Table 4 ). One patient underwent thrombolysis 13 for radial and ulnar artery thrombosis; the second patient underwent catheter-directed 14 thrombolysis on POD 0 and then embolectomy the subsequent day. Seven patients (33.3%) were 15 managed conservatively and two patients (9.5%) underwent primary amputation ( Table 5 ). The 16 four patients that required general anesthesia were intubated for the operation. The remaining (Table 5) . 20 Postoperative complications included pneumonia (41.7%), shock (41.7%), acute renal failure 21 (33.3%), cardiac arrest (33.3%), and myocardial infarction (16.7%) in the arterial group. The in- 22 hospital primary patency was 100% and major amputation rate was 0% during the duration of 23 J o u r n a l P r e -p r o o f this study. The mortality was 33.3% in the arterial group and 0% in the venous group. Of the 4 1 patients who expired, the cause of death was hypoxic respiratory failure leading to cardiac arrest 2 in three patients and septic shock in one patient. 3 out of 4 patients who expired were on 3 anticoagulation. Hospital length of stay was 8.33 days for all patients. 4 Risk factors that were more prevalent in patients with COVID-19 who expired include 5 general anesthesia (50.0% vs 18.18% p=0.22) and AKI on admission (75.0% v. 18.2%, p=0.04). 6 All mortalities occurred in females (100% v. 45.5%, p=0.057) and patients over 55 (100% v. 7 45.5%, p=0.057) ( Table 6 ). hypercoagulability and are at high risk for arterial and venous thromboembolism. There were 12 over 30 thrombotic complications during our study period. In comparison, during the 45-day 13 period preceding this study, there were only 9 interventions for acute thrombotic events of which 14 7 were arterial and 2 were venous cases. This translates to over a 3-fold increase in the rate of 15 thrombotic events. There is increasing evidence that patients with COVID-19 are prone to 16 thrombotic complications 12 . Some authors postulate that these events can potentially be 17 explained by disseminated intravascular coagulation (DIC) which is thought to contribute to 18 thrombotic complications in critically-ill septic COVID-19 patients 13 . However, in 38.1% of our 19 thrombotic cases, patients only had mild COVID-19 infections and no evidence of DIC. 20 Interestingly, the initial presentation in five cases (23.8%) was an acute thrombotic event without infection. It has been suggested that the severity of the inflammatory response correlates with the 2 severity of COVID-19 disease. 14 However, since we observed a majority of thrombotic events in 3 patients with mild COVID-19 symptoms, this suggests that the hypercoagulability risk of 4 COVID-19 may not be due to the degree of inflammatory response alone. There is increasing 5 evidence that there is a viral-induced endotheliitis and this may contribute to the 6 hypercoaguability. 15 

We identified several prevalent comorbidities in patients with thrombotic events, 8 including hypertension, hyperlipidemia, diabetes mellitus, and acute renal failure. These 9 comorbidities are much more prevalent in our cohort when compared to other reported cases of 10 COVID-19 in the literature and may be significant risk factors for thrombotic events 16 . 11 Interestingly, all patients who expired in our cohort were female and over 55 years of age. Both 12 female gender and older age have been shown to be a poor prognostic factor following vascular 13 surgery interventions. 17 Thus, both risk factors are also likely poor prognostic factors for 14 ischemic events following COVID-19 infection. 15 There are numerous studies that show COVID-19 patients have multiple laboratory 16 abnormalities, including decreased antithrombin levels, elevated d-dimer, decreased PTT 17 elevated fibrin-degradation products, and increased fibrinogen 10 . In our patients, there were 18 several markedly elevated laboratory values, including d-dimer, fibrinogen, and LDH. Although 19 more data is needed, perhaps elevated d-dimer and fibrinogen can be utilized as a marker for 20 patients who will be at high risk for thrombotic complications from COVID-19. Another notable 21 laboratory finding was a very high neutrophil:lymphocyte (NLR) ratio of 8.83. Other studies 22 have correlated a high NLR as a predictor for progression of COVID-19 infection 18 . In line with 23 this, our cohort had a high postoperative sepsis and mortality rate of 35.7% and 28.6%, 1 respectively. This may be due to progression of COVID-19 infection. It is hypothesized that the 2 virus acts on T lymphocytes and downstream sequalae may be an important factor in clot 3 formation and propagation 10 . Furthermore, there were elevated levels of procalcitonin only in 4 patients with arterial thrombosis but not venous events. Studies have shown an association 5 between procalcitonin and COVID-19 disease severity 19, 20 but the mechanism of this remains 6 unclear. 7 The acute vascular presentations of COVID-19 bring up several unique considerations 8 and important management strategies. First, all patients during the pandemic who present with 9 thrombotic events should undergo COVID-19 testing as this may be a major risk factor. This is 10 particularly important in patients who are young or who have no significant risk factors for 11 thrombosis. Additionally, based on our experience and current available data, we recommend 

The decision to intervene on patients with COVID-19 and an acute thrombotic event 19 must carefully be evaluated. The threshold to intervene will depend on the respiratory status, 20 severity of ischemia, and overall prognosis. Although varying rates are reported in the literature, 21 the risk of mortality following COVID-19 infections is approximately 3.7% 23 . In our cohort, the suggesting venous thrombosis has a much better prognosis. The majority of arterial cases also 3 had significant complications, including pneumonia, intubation or reintubation, myocardial 4 infarction, and acute renal failure. However, the short-term primary patency was 100% with no 5 reoperations for major amputation. Thus, although acute arterial thrombotic events are a poor 6 prognostic marker for complications and mortality, short-term patency and limb salvage rates 7 remain high. The risk factors we identified for mortality which include age over 55 years, 8 preoperative AKI, and female gender should also be considered when determining optimal 9 management. Additionally, there may be a reduction in mortality if local or regional anesthesia is 10 used to avoid intubation. In early reports, the mortality rate of patients with COVID-19 who 11 require intubation exceeds 80% 24, 17 . 19.1% of patients in our study underwent general 12 anesthesia. We found a much higher mortality rate (50.0% vs 18.1%, p =0.22) in patients who 13 required intubation. These patients were intubated for the procedure in the operating room and 14 thus avoiding general anesthesia in these patients may be critical to reducing perioperative 15 mortality. 16 There are several limitations to our study. First, the number of acute thrombotic events at 17 our institution is likely higher than what is reported in this study. In part, this may be from false 18 negative tests with nasal swabs which was routinely used in our institution during this time 19 period. The rate of false negatives from PCR COVID-19 testing can exceed 30% 25 . Thus, 20 patients with symptoms consistent with COVID-19 but negative testing were excluded from the 21 study. Additionally, patient data was obtained through vascular surgery consultation in the health 

COVID-19 infection typically presents with respiratory symptoms such as fever, cough, 13 or shortness of breath. However, there is increasing evidence of a viral induced 14 hypercoagulability in COVID-19 infections which may not correlate with severity of infection. 15 We describe our experience in the epicenter of the pandemic of over 20 patients who 16 experienced major thrombotic events from COVID-19. Our cohort highlights the need for give this person the authority to submit this form, the manuscript text, figures, tables, and all other accompanying files to the Journal of Vascular Surgery Publications. The authors also authorize the corresponding author to communicate with the Editorial Office and the Publisher regarding the submission, peer-review, revision, and publication of this manuscript on behalf of the authors.

The COVID-19 Pandemic in the US: A Clinical Update

COVID-19)

New York City Region Is Now an Epicenter of the Coronavirus Pandemic

What we know so far: COVID-19 current clinical knowledge and research

Clinical observation and management of COVID-19 patients

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Endothelial cell infection and endotheliitis in COVID-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Chinese Center for Disease Control and Prevention

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation

Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China

Endotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Lessons learned from the analysis of gender effect on risk factors and procedural outcomes of lower extremity arterial disease

Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor

Characterization of the heparin-binding properties of IL-6

CORRESPONDING AUTHOR RESPONSIBILITY. The corresponding author confirms that they and the co-authors have read and agreed to follow the policies of the Journal of Vascular Surgery Publications. The corresponding author also confirms that they and the co-authors have approved the manuscript files, disclosed all relevant conflicts of interest, and verified their contributions and conflicts on this form prior to submission. The corresponding author is responsible for serving these same functions for the revision and resubmission of this work. ☒ COMPLETELY ORIGINAL. The authors certify that this manuscript is original, has been written by the stated authors, has not been published previously, and is not under consideration for publication by another journal. ☐ FOLLOW UP. This work is a follow up from a previously published study. It contains a patient cohort that has been reported previously. to indicate their involvement in the creation of this manuscript. It is important that a box is checked in each authorship category, otherwise the person will not qualify for authorship and the manuscript will be returned to the authors for correction.The boxes for "Approval" and Accountability" must be checked for ALL authors. If an author declines to approve or be accountable for the work, they may not be included as authors.CRITERIA REQUIRED FOR AUTHORSHIP. Authors must have contributed in all four categories.

including study design and conception; data collection; or data analysis and interpretation 

☒ SHARED FIRST AUTHORSHIP: Check this box if two authors participated equally and should share "first authorship".List these as first and second authors. Shared first authorship between Nicole Ilonzo and Ajit Rao SHARED SENIOR AUTHORSHIP: If two authors participated equally and should share "senior authorship" enter their initials here:

EACH author must disclose all relevant financial and nonfinancial potential conflicts of interest with respect to this manuscript. Potential conflicts of interest include, but are not limited to:1. A financial contribution to the author or the authors' institution from a company or organization that might benefit (or lose) financially from the results, conclusions or discussion presented in the manuscript Examples include: Royalties, Patents (or patents pending), fees for consulting, fees for speaking when organized by a corporate sponsored speakers' bureau, funds for a member of the author's staff or family 2. Ownership of stocks, shares or options in a company or organization that might benefit (or lose) financially from the results, conclusion or discussion presented in the paper/letter 3. A commercial interest in the form of a relationship with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients 4. Other potential conflicts include: a. an academic association or antagonism with someone whose interest might be affected by the paper b. membership in a special interest group whose interests might be affected by the paper c. other strong convictions that might have affected what was written

Example:KR has been paid a consulting fee by XYZ Company and is on their speakers' bureau, PW has shares in LMN company, RC received funding for a research assistant from the XYZ Company, JB has no conflicts of interest.J o u r n a l P r e -p r o o f

Each author must disclose the name and involvement of all entities that provided financial support for this work. Please list the funding (grant, scholarships, donated devices, etc.) and describe the involvement of each sponsor in the: 1. Study design; collection, analysis, and interpretation of data; 2. Manuscript writing 3. The decision to submit the manuscript for publication 4. Any other involvement in the creation of the manuscript (Artwork, critical revision, etc.)

The authors must make a meaningful disclosure regarding their discussions of off label or unapproved drugs or devices.☐ This study does include off label drugs and/or devices.The specific names of the products discussed are: Click or tap here to enter text.☒ This study does not include off label drugs and/or devices.The corresponding author confirms that they and the co-authors believe that this form and all accompanying files describe truthful facts. The corresponding author also certifies that they and each co-author have participated to a sufficient degree to take public responsibility for this manuscript, that their contributions and relevant conflicts of interest are accurately and completely reported on this form.